Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Intra-Arterial Treatment Highly Effective for Stroke

By HospiMedica International staff writers
Posted on 30 Dec 2014
A new study suggests that intra-arterial treatment for emergency revascularization administered within six hours of acute ischemic stroke is both effective and safe. More...


Researchers at Erasmus Medical Center (EMC; Rotterdam, The Netherlands) and other Dutch institutions participating in the MR CLEAN study randomly assigned 500 patients (mean age 65 years) at 16 medical centers in the Netherlands to either intra-arterial treatment plus usual care (233 patients) or usual care alone (267 patients). Eligible patients had a proximal arterial occlusion in the anterior cerebral circulation that was confirmed on vessel imaging, and that could be treated intra-arterially within six hours after symptom onset. The primary outcome was modified Rankin scale score at 90 days.

The results showed that 445 of the patients (89%) were treated with intravenous alteplase before randomization. Retrievable stents were used in 81.5% of the patients assigned to intra-arterial treatment. The researchers found an absolute difference of 13.5% in the rate of functional independence (modified Rankin score, 0–2) in favor of the intervention (32.6% versus 19.1%). There were no significant differences in mortality or in the occurrence of symptomatic intracerebral hemorrhage. The study was published on December 17, 2014, in the New England Journal of medicine (NEJM).

“Intra-arterial treatment consisted of arterial catheterization with a microcatheter to the level of occlusion and delivery of a thrombolytic agent, mechanical thrombectomy, or both,” concluded lead author Olvert Berkhemer, MD, of EMC, and colleagues. “This treatment leads to a clinically significant increase in functional independence in daily life by three months, without an increase in mortality.”

Intravenous alteplase administered within 4.5 hours after symptom onset is the only reperfusion therapy with proven efficacy in patients with acute ischemic stroke. However, well-recognized limitations of this therapy include the narrow therapeutic time window and contraindications such as recent surgery, coagulation abnormalities, and a history of intracranial hemorrhage. Moreover, intravenous alteplase appears to be less effective at opening proximal occlusions of the major intracranial arteries, which account for more than one third of cases of acute anterior-circulation stroke.

Related Links:

Erasmus Medical Center



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.